Melatonin improves mitochondrial function in inguinal white adipose tissue of Zücker diabetic fatty rats

Journal of Pineal Research

Volumn 57, Issue 1, 2014, Pages 103-109

  Jimenéz Aranda, Aroa ^a   Fernández Vázquez, Gumersindo ^b   Mohammad A Serrano, María ^a   Reiter, Russel J ^c   Agil, Ahmad ^a,d  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

beige adipose tissue; melatonin; mitochondrial function; white adipose tissue; Z cker diabetic fatty rats

Indexed keywords

CALCIUM; DRINKING WATER; MELATONIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NITRITE; SUPEROXIDE DISMUTASE;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEIGE ADIPOSE TISSUE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DISSECTION; ENZYME ACTIVITY; INGUINAL REGION; MALE; METABOLISM; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RAT; REDUCTION; RESPIRATION CONTROL; WHITE ADIPOSE TISSUE; ANIMAL; CELL RESPIRATION; DRUG EFFECTS; MITOCHONDRION; ZUCKER RAT;

ADIPOSE TISSUE, WHITE; ANIMALS; CALCIUM; CELL RESPIRATION; MALE; MELATONIN; MITOCHONDRIA; RATS; RATS, ZUCKER;

EID: 84904471217     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12147     Document Type: Article

References (55)

1. Kim JA, Wei Y, Sowers JR,. Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008; 102: 401-414.
2. Goodpaster BH,. Mitochondrial deficiency is associated with insulin resistance. Diabetes 2013; 62: 1032-1035.
3. Patti M-E, Corvera S,. The Role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 2010; 31: 364-395.
4. Brand MD, Nicholls DG,. Assessing mitochondrial dysfunction in cells. Biochem J 2011; 435: 297-312.
5. Kusminski CM, Scherer PE,. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol Metab 2012; 23: 435-443.
6. Maassen JA, Romijn JA, Heine RJ,. Fatty acid-induced mitochondrial uncoupling in adipocytes as a key protective factor against insulin resistance and beta cell dysfunction: a new concept in the pathogenesis of obesity-associated type 2 diabetes mellitus. Diabetologia 2007; 50: 2036-2041.
7. De Pauw A, Tejerina S, Raes M, et al. Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations. Am J Pathol 2009; 175: 927-939.
8. Stehle JH, Saade A, Rawashdeh O, et al. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res 2011; 51: 17-43.
9. Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 2014; [Epub ahead of print].
10. Hardeland R, Madrid JA, Tan DX, et al. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res 2012; 52: 139-166.
11. Cardinali DP, Srinivasan V, Brzezinski A, et al. Melatonin and its analogs in insomnia and depression. J Pineal Res 2012; 52: 365-375.
12. Tan DX, Chen L, Poeggeler B, et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1: 57-60.
13. Reiter RJ, Paredes SD, Manchester LC, et al. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
14. Galano A, Tan DX, Reiter RJ,. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res 2013; 54: 245-257.
15. Bonnefont-Rousselot D, Collin F,. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology 2010; 278: 55-67.
16. Galano A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
17. Tan DX, Manchester LC, Fuentes-Broto L, et al. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev 2011; 12: 167-188.
18. Paradies G, Petrosillo G, Paradies V, et al. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010; 48: 297-310.
19. Escames G, Ozturk G, Baño-Otálora B, et al. Exercise and melatonin in humans: reciprocal benefits. J Pineal Res 2012; 52: 1-11.
20. Wolden-Hanson T, Mitton DR, McCants RL, et al. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 2000; 141: 487-497.
21. Prunet-Marcassus B, Desbazeille M, Bros A, et al. Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology 2003; 144: 5347-5352.
22. Raskind MA, Burke BL, Crites NJ, et al. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 2007; 32: 284-288.
23. Agil A, Navarro-Alarcõn M, Ruiz R, et al. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. J Pineal Res 2011; 50: 207-212.
24. Terrõn MP, Delgado-Adámez J, Pariente JA, et al. Melatonin reduces body weight gain and increases nocturnal activity in male Wistar rats. Physiol Behav 2013; 118: 8-13.
25. Jiménez-Aranda A, Fernández-Vázquez G, Campos D, et al. Melatonin induces browning of inguinal white adipose tissue in Zücker diabetic fatty rats. J Pineal Res 2013; 55: 416-423.
26. Acuña-Castroviejo D, Lopez LC, Escames G, et al. Melatonin mitochondria interplay in health and disease. Curr Top Med Chem 2011; 11: 221-240.
27. Cardinali DP, Furio AM, Brusco LI,. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Curr Neuropharmacol 2010; 8: 218-227.
28. Kilic U, Yilmaz B, Ugur M, et al. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia. J Pineal Res 2012; 52: 228-235.
29. Zavodnik IB, Lapshina EA, Cheshchevik VT, et al. Melatonin and succinate reduce rat liver mitochondrial dysfunction in diabetes. J Physiol Pharmacol 2011; 62: 421-427.
30. Subramanian P, Mirunalini S, Pandi-Perumal SR, et al. Melatonin treatment improves the antioxidant status and decreases lipid content in brain and liver of rats. Eur J Pharmacol 2007; 571: 116-119.
31. Gonzalez MA, Contini MD, Millen N, et al. Role of melatonin in the oxidative damage prevention at different times of hepatic regeneration. Cell Biochem Funct 2012; 30: 701-708.
32. Bruck R, Aeed H, Avni Y, et al. Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rats. J Hepatol 2004; 40: 86-93.
33. Rodriguez MI, Escames G, Lõpez LC, et al. Melatonin administration prevents cardiac and diaphragmatic mitochondrial oxidative damage in senescence-accelerated mice. J Endocrinol 2007; 194: 637-643.
34. Wang WZ, Fang X-H, Stephenson LL, et al. Melatonin attenuates I/R-induced mitochondrial dysfunction in skeletal muscle. J Surg Res 2011; 171: 108-113.
35. Yang Y, Duan W, Jin Z, et al. JAK2/STAT3 activation by melatonin attenuates the mitochondrial oxidative damage induced by myocardial ischemia/reperfusion injury. J Pineal Res 2013; 55: 275-286.
36. Andrabi SA, Sayeed I, Siemen D, et al. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for antiapoptotic effects of melatonin. FASEB J 2004; 18: 869-871.
37. Kinnally KW, Peixoto PM, Ryu S-Y, et al. Is mPTP the gatekeeper for necrosis, apoptosis, or both? Biochim Biophys Acta 2011; 1813: 616-622.
38. Gnaiger E, Kuznetsov AV, Schneeberger S, et al. Mitochondria in the cold. In: Life in the Cold., Heldmaier G, Klingenspor M, eds., Springer, New York, 2000; pp. 431-442.
39. Haller T, Ortner M, Gnaiger E,. A respirometer for investigating oxidative cell metabolism: toward optimization for respiratory studies. Anal Biochem 1994; 218: 338-342.
40. Pacher P, Beckman JS, Liaudet L,. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315-424.
41. Crompton M, Ellinger H, Costi A,. Inhibition by cyclosporin A of a Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 1988; 255: 357-360.
42. Lõpez A, García JA, Escames G, et al. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J Pineal Res 2009; 46: 188-198.
43. Cheshchevik VT, Dremza IK, Lapshina EA, et al. Corrections by melatonin of liver mitochondrial disorders under diabetes and acute intoxication in rats. Cell Biochem Funct 2011; 29: 481-488.
44. Okatani Y, Wakatsuki A, Reiter RJ, et al. Hepatic mitochondrial dysfunction in senescence-accelerated mice: correction by long-term, orally administered physiological levels of melatonin. J Pineal Res 2002; 33: 127-133.
45. Leõn J, Acuña-Castroviejo D, Escames G, et al. Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005; 38: 1-9.
46. Petrosillo G, Di Venosa N, Pistolese M, et al. Protective effect of melatonin against mitochondrial dysfunction associated with cardiac ischemia-reperfusion: role of cardiolipin. FASEB J 2006; 20: 269-276.
47. Patki G, Lau YS,. Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease. Pharmacol Biochem Behav 2011; 99: 704-711.
48. Rosales-Corral S, Acuna-Castroviejo D, Tan D-X, et al. Accumulation of exogenous amyloid-beta peptide in hippocampal mitochondria causes their dysfunction: a protective role for melatonin. Oxid Med Cell Longev 2012; 2012:Article ID 843649.
49. Hunter DR, Haworth RA,. The Ca2+-induced membrane transition in mitochondria. I. The protective mechanisms. Arch Biochem Biophys 1979; 195: 453-459.
50. Haworth RA, Hunter DR,. The Ca2+-induced membrane transition in mitochondria. II. Nature of the Ca2+ trigger site. Arch Biochem Biophys 1979; 195: 460-467.
51. Hunter DR, Haworth RA,. The Ca2+-induced membrane transition in mitochondria. III. Transitional Ca2+ release. Arch Biochem Biophys 1979; 195: 468-477.
52. Rao VK, Carlson EA, Yan SS,. Mitochondrial permeability transition pore is a potential drug target for neurodegeneration. Biochim Biophys Acta 2013; doi: 10.1016/jbbadis.2013.09.003.
53. Brenner C, Moulin M,. Physiological roles of the permeability transition pore. Circ Res 2012; 111: 1237-1247.
54. Elrod JW, Molkentin JD,. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ J 2013; 77: 1111-1122.
55. Petrosillo G, Colantuono G, Moro N, et al. Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Am J Physiol Heart Circ Physiol 2009; 297: H1487-H1493.